echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Bojian AD new drug price cuts by 50%

    Bojian AD new drug price cuts by 50%

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 20, Biogen announced that it would reduce the wholesale acquisition cost of the new Alzheimer’s disease drug Aduhelmd (100mg/ml specification) by approximately 50% from January 1, 2022


    Bojian CEO Michel Vounatsos said that in the past few months, we have been listening to feedback from various stakeholders, and today we have taken an important step to improve the accessibility of Aduhelmd


    Bojian's move is aimed at reducing the out-of-pocket expenses of AD patients using Aduhelmd and reducing the burden on the US healthcare system


    Bojian's lowering of Aduhelmd's price has a lot to do with its poorer-than-expected sales performance after listing


    On December 17, the European Medicines Agency (EMA) Committee for Medicines for Human Use (CHMP) also held a negative opinion on the marketing right application (MAA) of Aduhelm (aducanumab) for the treatment of early Alzheimer's disease


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.